Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Lisocabtagene maraleucel (liso-cel) has shown promising efficacy in clinical trials for patients with relapsed/refractory large B-cell lymphoma (LBCL). We present health-related quality of life (HRQOL) results from the TRANSFORM study, the first comparative analysis of liso-cel vs standard of care (...

Descripción completa

Detalles Bibliográficos
Autores principales: Abramson, Jeremy S., Johnston, Patrick B., Kamdar, Manali, Ibrahimi, Sami, Izutsu, Koji, Arnason, Jon, Glass, Bertram, Mutsaers, Pim, Lunning, Matthew, Braverman, Julia, Liu, Fei Fei, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Guo, Shien, Shi, Ling, Solomon, Scott R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713278/
https://www.ncbi.nlm.nih.gov/pubmed/36149968
http://dx.doi.org/10.1182/bloodadvances.2022008106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713278/
https://www.ncbi.nlm.nih.gov/pubmed/36149968
http://dx.doi.org/10.1182/bloodadvances.2022008106

Ejemplares similares